Avid Bioservices (NASDAQ:CDMO) Shareholders Have Enjoyed An Impressive 232% Share Price Gain

The Avid Bioservices, Inc. (NASDAQ:CDMO) share price has had a bad week, falling 14%. In contrast, the return over three years has been impressive. Indeed, the share price is up a very strong 232% in that time. To some, the recent share price pullback wouldn't be surprising after such a good run. Only time will tell if there is still too much optimism currently reflected in the share price.

View 2 warning signs we detected for Avid Bioservices

Avid Bioservices wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last 3 years Avid Bioservices saw its revenue shrink by 6.4% per year. So we wouldn't have expected the share price to gain 49% per year, but it has. It's fair to say shareholders are definitely counting on a bright future.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

NasdaqCM:CDMO Income Statement, January 6th 2020
NasdaqCM:CDMO Income Statement, January 6th 2020

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free report showing analyst forecasts should help you form a view on Avid Bioservices

Advertisement

A Different Perspective

We're pleased to report that Avid Bioservices shareholders have received a total shareholder return of 55% over one year. There's no doubt those recent returns are much better than the TSR loss of 7.5% per year over five years. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

MI
mitchell_lawler
mitchell_lawler

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it. cover
98
ZO
zoe_vi5fn

Any moat with an opt-out clause for your competitors is just a fence around your own garden.

CO
connor_iwn1g

Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.

Andrew Legget

Great earnings season, but are the earnings real?

Great earnings season, but are the earnings real? cover
At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.
10

About NasdaqCM:CDMO

Avid Bioservices

Operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States.

Slightly overvalued with limited growth.

Advertisement

Weekly Picks

LO
Lou_Basenese
ONCY logo
Lou_Basenese on Oncolytics Biotech ·

The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech

Fair Value:US$3.575.5% undervalued
23 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
TR
tripledub
Recommended Voice
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$5861.4% undervalued
59 users have followed this narrative
3 users have commented on this narrative
34 users have liked this narrative
TA
Talos
Emerging Author
VOYG logo
Talos on Voyager Technologies ·

The "Landlord of Orbit" – A Deep Value Play Ahead of the Starlab Era

Fair Value:US$385.291.1% undervalued
58 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
IV
Emerging Author
UBER logo
Ivoed on Uber Technologies ·

Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides

Fair Value:US$11632.1% undervalued
11 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

AC
INTC logo
achillez_97613 on Intel ·

Fair Value = $110, Bull = $150, Bear = $65.

Fair Value:US$56.0559.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RE
AGFB logo
RecMag on Agfa-Gevaert ·

Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.

Fair Value:€5.3991.4% undervalued
28 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
LU
LunaRodas
FRO logo
LunaRodas on Frontline ·

FRO | Frontline: What They Said vs. What They Did

Fair Value:US$34.0729.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
365 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9122.3% overvalued
213 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0943.9% undervalued
238 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative